. Author manuscript; available in PMC: 2022 Jul 1.

Published in final edited form as: J Acquir Immune Defic Syndr. 2021 Jul 1;87(3):1002–1009. doi: 10.1097/QAI.0000000000002661

Table 1:

Baseline characteristics in all dolutegravir recipients

	Participants with genetic consent		Participants without genetic consent
	DTG, TAF and FTC	DTG, TDF and FTC	DTG, TAF or TDF and FTC
	n=154	n=166	n= 362
Age in years, (IQR)	32 (27, 38)	32 (27, 37)	32 (26, 37)
Sex
Male, n (%)	65 (37.4%)	61 (36.8%)	154 (42.5%)
Female, n (%)	109 (62.6%)	105 (63.3%)	208 (57.5%)
Baseline BMI, kg/m²(IQR)	23.6 (20.6, 26.5)	23.0 (20.0, 27.1)	23.1 (20.1, 27.0)
Weight gain at week 48, kg (IQR)	+5.8 (+2.4, +9.4)	+2.5 (0.0 +5.6)	+2.9 (+0.2, +7.6)
Baseline CD4 count (IQR)	326 (170, 502)	272 (159, 424)	295 (173, 451)
Baseline viral load (IQR)	28 968 (6 180, 75 314)	25 703 (6 408, 75 619)	22 064 (5 973, 73 796)
Viral load suppression (< 50 c/μL) at week 48, n (%)	164 (95.9%)	157 (96.3%)	262 (92.6%)

IQR =interquartile range, kg= kilograms, DTG=dolutegravir, TAF= tenofovir alafenamide, FTC= emtricitabine, TDF= tenofovir disoproxil fumarate